Gastric cancer represents one of the leading causes of cancer-related death worldwide. Even if the last decade has witnessed an improvement in surgical and systemic treatments, with an increase of overall life expectancy, survival rates still remain unsatisfactory, especially for patients with metastatic disease. Systemic therapies represent the gold standard in the management of stage IV gastric cancer. In this scenario, the availability of effective second and third lines has represented for a long time the only hope to offer an overall survival improvement to these patients. Recently, the advent of immune checkpoint inhibitors has involved also gastric cancer with encouraging efficacy data in the metastatic setting, becoming integral part of the management of selected patients.

Does immunotherapy change the treatment paradigm in metastatic gastric cancer? / Camera, Silvia; Liscia, Nicole; Foti, Silvia; Barbieri, Lavinia; Cossu, Andrea; Puccetti, Francesco; Elmore, Ugo; Rosati, Riccardo; Scartozzi, Mario; Mazza, Elena; Cascinu, Stefano. - In: MEDICAL ONCOLOGY. - ISSN 1559-131X. - 39:12(2022). [10.1007/s12032-022-01819-4]

Does immunotherapy change the treatment paradigm in metastatic gastric cancer?

Puccetti, Francesco;Elmore, Ugo;Rosati, Riccardo;Mazza, Elena
Penultimo
;
Cascinu, Stefano
Ultimo
2022-01-01

Abstract

Gastric cancer represents one of the leading causes of cancer-related death worldwide. Even if the last decade has witnessed an improvement in surgical and systemic treatments, with an increase of overall life expectancy, survival rates still remain unsatisfactory, especially for patients with metastatic disease. Systemic therapies represent the gold standard in the management of stage IV gastric cancer. In this scenario, the availability of effective second and third lines has represented for a long time the only hope to offer an overall survival improvement to these patients. Recently, the advent of immune checkpoint inhibitors has involved also gastric cancer with encouraging efficacy data in the metastatic setting, becoming integral part of the management of selected patients.
2022
Clinical practice
Immunotherapy
Metastatic gastric cancer
Systemic treatment
File in questo prodotto:
File Dimensione Formato  
1.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 704.4 kB
Formato Adobe PDF
704.4 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/132052
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact